Showing 3661-3670 of 5621 results for "".
- TheiaNova Selected as Finalist at Eyecelerator for Keratoconus Therapy; Launches Capital Raise for Clinical Trialshttps://modernod.com/news/theianova-selected-as-finalist-at-eyecelerator-for-keratoconus-therapy-launches-capital-raise-for-clinical-trials/2482215/New Zealand-based TheiaNova has delivered the company’s pitch as a finalist in the renowned Eyecelerator event in Boston. At the Eyecelerator event, where TheiaNova participated as a finalist, CEO Carissa Fonseca announced the company’s efforts to raise $10 million 
- Eversight Center Awards 2024 Eye & Vision Research Grantshttps://modernod.com/news/eversight-center-awards-2024-eye-vision-research-grants/2482211/The Eversight Center for Vision and Eye Banking Research in Cleveland, Ohio, recently announced it has awarded four grants to investigators at Tufts University in Boston, Massachusetts; Wayne State University in Detroit, Michigan; and University of Michigan in Ann Arbor, Michigan, to advance prom
- Zeiss Completes Acquisition of Dutch Ophthalmic Research Center (DORC)https://modernod.com/news/carl-zeiss-meditec-completes-acquisition-of-dutch-ophthalmic-research-center/2482210/Carl Zeiss Meditec announced it has secured all required regulatory approvals and completed the acquisition of Dutch Ophthalmic Research Center (DORC). IN December, Zeiss announced its plans to acquire from the investment firm Eurazeo SE (Paris, France) for about €985 million ($1.0
- Nordic Pharma to Present Data on Lacrifill Canaliocular Gel, a Novel Therapy for Dry Eye, at ASCRShttps://modernod.com/news/nordic-pharma-to-present-data-on-lacrifill-canaliocular-gel-a-novel-therapy-for-dry-eye-at-ascrs/2482202/Nordic Pharma will be presenting data on Lacrifill Canalicular Gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Boston, on April 5-8, 2024. Lacrifill Canalicular Gel is a cross-linked hyaluronic acid derivativ
- Haag-Streit Launches Eyesi Indirect Ophthalmoscope ROP Simulator for Retinal Examinations on Preterm Infantshttps://modernod.com/news/haag-streit-launches-eyesi-indirect-ophthalmoscope-rop-simulator-for-retinal-examinations-on-preterm-infants/2482200/Haag-Streit has launched the Eyesi Indirect Ophthalmoscope ROP Simulator for training of retinal examinations on premature babies and classification of retinopathy of prematurity (ROP). The high-fidelity training system is designed to allow residents to practice device handling and
- Aldeyra Plans to Resubmit New Drug Application for Reproxalap in Dry Eye Diseasehttps://modernod.com/news/aldeyra-plans-to-resubmit-new-drug-application-for-reproxalap-in-dry-eye-disease/2482193/About 4 months after receiving a complete response letter (CRL) from the FDA, Aldeyra Therapeutics announced a clinical development plan intended to enable resubmission of a new drug application (NDA) of topical ocular 0.25% reproxalap, an investigational RASP modulator, for the treatment of dry
- Nanoscope Announces Topline Results from Phase 2b Trial of MCO-010 for Retinitis Pigmentosahttps://modernod.com/news/nanoscope-announces-topline-results-from-randomized-phase-2b-trial-of-mco-010-for-retinitis-pigmentosa/2482183/Nanoscope Therapeutics announced positive topline results after the completion of the 2-year phase 2b RESTORE randomized, controlled clinical trial of its lead program, MCO-010, a mutation-agnostic gene therapy for patients with permanent and severe vision loss from advanced retini
- Opus Genetics Completes Dosing in First Cohort of Phase 1/2 Trial of Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-completes-dosing-in-first-cohort-of-phase-12-trial-of-gene-therapy-opgx-lca5-in-patients-with-lca5/2482180/Opus Genetics announced that the first cohort has completed dosing in its open-label, dose-escalation phase 1/2 clinical trial evaluating the subretinal delivery of OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the oute
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef